<DOC>
	<DOCNO>NCT00265057</DOCNO>
	<brief_summary>N-cadherin , protein involved blood vessel cell binding , increase cancer progress , surface many tumor cell . ADH-1 block N-cadherin . This study test safety effect ADH-1 subject incurable , solid tumor protein biomarker call N-cadherin . This study identify amount ADH-1 subject tolerate .</brief_summary>
	<brief_title>Study ADH-1 Given Intravenously Patients With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Signed write informed consent Male female patient &gt; = 18 year age solid tumor ( ) refractory standard curative therapy curative therapy exists . Study currently enrol patient nonsmall cell lung cancer advance ovarian cancer safety expansion phase . Clinically radiologically document measurable disease . Immunohistochemical evidence Ncadherin expression ( least 1+ positive ) archive fresh tumor tissue Adequate performance status organ function , evidence hematological biochemical blood test electrocardiogram ( ECG ) Exclusion criterion : Receipt ADH1 prior clinical study Chemotherapy , radiotherapy , investigational drug within 30 day study entry History primary brain tumor brain metastasis ( know suspect ) unless lesion completely resolve follow appropriate treatment recurrence least 6 month . History spinal cord compression . History tumor show clinically significant evidence active bleeding ( e.g. , gross hemoptysis , hematemesis , hematuria , melena , bleed superficial tumor ) within 12 week study entry . Stroke , major surgery , major tissue injury within 30 day study entry History congestive heart failure , myocardial infarction , angina , life threaten arrhythmia , significant electrocardiogram ( ECG ) abnormality , know hypercoagulable state</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Cancer ;</keyword>
	<keyword>Tumors ;</keyword>
	<keyword>Neoplasms ;</keyword>
	<keyword>Anticarcinogenic Agents ;</keyword>
	<keyword>Antineoplastic Agents ;</keyword>
	<keyword>Cadherins ;</keyword>
	<keyword>Non-Small-Cell Lung Carcinoma ;</keyword>
	<keyword>Ovarian Cancer</keyword>
</DOC>